Provided by Tiger Fintech (Singapore) Pte. Ltd.

Humacyte, Inc.

2.31
-0.2000-7.97%
Pre-market: 2.30-0.0100-0.43%04:00 EDT
Volume:4.23M
Turnover:9.92M
Market Cap:358.32M
PE:-3.57
High:2.50
Open:2.50
Low:2.25
Close:2.51
Loading ...

Humacyte, Trestle Biotherapeutics announce research collaboration

TIPRANKS
·
06 Mar

Trestle Bio Announces Research Collaboration With Humacyte

THOMSON REUTERS
·
06 Mar

Trestle Bio Announces Research Collaboration with Humacyte

Business Wire
·
06 Mar

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

GlobeNewswire
·
03 Mar

Humacyte Shares Rise After Receiving US Patent for Bioreactor Manufacturing System

MT Newswires Live
·
28 Feb

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess and Other Bioengineered Tissues

THOMSON REUTERS
·
27 Feb

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

GlobeNewswire
·
27 Feb

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
26 Feb

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

GlobeNewswire
·
26 Feb

When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven?

Simply Wall St.
·
19 Feb

Humacyte, Pluristyx Announce Gene Editing Partnership

MT Newswires Live
·
29 Jan

Humacyte, Pluristyx announce expanded partnership

TIPRANKS
·
28 Jan

Humacyte and Pluristyx Announce Gene Editing Partnership to Support Biovascular Pancreas (Bvp™) Development Using Ipscs

THOMSON REUTERS
·
28 Jan

Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs

GlobeNewswire
·
28 Jan

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
21 Jan

Humacyte announces planned IND filing in 2025 for sdATEV for CABG

TIPRANKS
·
21 Jan

Humacyte Announces Planned Ind Filing in 2025 to Support First-in-Human Clinical Study of Small-Diameter Atev™ for Coronary Artery Bypass Grafting

THOMSON REUTERS
·
21 Jan

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

GlobeNewswire
·
21 Jan

HUMA Lawsuit Alert! Class Action Against Humacyte, Inc.

TIPRANKS
·
16 Jan